Spring direct naar de hoofdnavigatie of de inhoud

New on Kluwer Patent Blog: G.D. Searle v. Sandoz B.V., Netherlands

The Court concluded that the compound darunavir was not protected by a patent within the sense of Art. 3 of the SPC directive because, following the CJEU decision in Teva v Gilead, it is necessary that the compound for which the SPC is granted can be specifically identified in the patent.

Read the full article by Bart van Wezenbeek on Kluwer IP Law.

Also see these experts

Hajo Kraak

Hajo Kraak

  • European and Dutch Patent Attorney
  • Partner
Frits Schut

Frits Schut

  • European and Dutch Patent Attorney
  • Partner
More experts